Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued

GAITHERSBURG, Md., June 29, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announce

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification va

https://www.cdc.gov/ebola/situation-summary/index.html

Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food a

Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 mill

Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analy

Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority

The executed agreement is valued at approximately $50 million, of which $36 million is contingent on

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substiph

Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Ser

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at app

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) wit

U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech

Emergent BioSolutions (NYSE:EBS) sees FY2026 sales of $720.000 million-$760.000 million vs $1.155 bi

Emergent BioSolutions (NYSE:EBS) reported quarterly losses of $(0.43) per share which missed the ana

Emergent BioSolutions Inc. (EBS) stock rose Friday as FDA approved new multipack configurations of o

Today, Emergent BioSolutions (NYSE:EBS) announced that the U.S. Food and Drug Administration (FDA) h

New York Attorney General sued the former CEO of Emergent BioSolutions, Robert G. Kramer, for inside

https://ag.ny.gov/press-release/2026/attorney-general-james-sues-former-ceo-emergent-biosolutions-in

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as

"This significant milestone reflects strong progress in improving our overall financial/cash pos

Today Emergent BioSolutions (NYSE:EBS) announced it has received a delivery order valued at up to $2

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) wi

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Emergent BioSolutions (NYSE:EBS) wi

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has received a $30 million contract modific